Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanced solid tumours. Patients received a median of two courses (range 1–5) at one of nine dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, A, Punt, C J A, Piccart, M J, Tellingen, O Van, Manen, L Van, Kerger, J, Groot, Y, Wanders, J, Verweij, J, Wagener, D J Th
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362731/
https://www.ncbi.nlm.nih.gov/pubmed/10188890
http://dx.doi.org/10.1038/sj.bjc.6690232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362731/
https://www.ncbi.nlm.nih.gov/pubmed/10188890
http://dx.doi.org/10.1038/sj.bjc.6690232

Ejemplares similares